University of Arkansas (UARK# 2017-03): A Single-Arm, Open-label Study of Anti-SLAMF7 mAb Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma (Total Therapy 8)
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2018
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms UARK# 2017-03
- 04 Oct 2017 Planned primary completion date changed from 1 Jan 2020 to 1 Jun 2020.
- 04 Oct 2017 Status changed from not yet recruiting to recruiting.
- 17 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 1 Sep 2017.